NCT04585477 2026-02-10Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)Stanford UniversityPhase 2 Recruiting80 enrolled
NCT04767009 2025-04-30SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint InhibitorsFudan UniversityPhase 2 Recruiting59 enrolled